Published in Cancer Weekly, March 15th, 1999
The program will use a model of BCC developed at UCSF. A team, headed by Ervin Epstein, MD, UCSF clinical professor of dermatology, will assess the safety and efficacy of a variety of novel pharmacological agents in treating the disease. Ontogeny will evaluate its lead compounds to determine in vivo activity against this cancer. Compounds demonstrating efficacy in this model will move forward in the company's clinical...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.